Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR005277)
Formula
SVG example
Phosphorylation
Reactant Fluorouracil Product 5-fluorodeoxyuridine-monophosphate
Reactant Info Product Info
Metabolic Type Conjugation - Phosphorylation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR009800 5-FP 5-Fluoruracil (5-FU) Unclear - Unclear 5-FP [1]
MR010706 Emtricitabine Emtricitabine Metabolite M7 Unclear - Unclear Emtricitabine [2]
MR001058 Floxuridine 5-fluorouracil Unclear Floxuridine [3], [4]
MR006727 Flucytosine 5-FU Unclear Flucytosine [5]
MR009468 1-ethoxymethyl-5-fluorouracil 5-FU Unclear - Unclear EMITEFUR [6]
MR005270 5'-hydroxytegafur Fluorouracil Other reaction - Degradation Tegafur [7], [8]
MR005272 5-hydroxytegafur Fluorouracil Multi-steps Reaction - Hydrolysis; oxidation Tegafur-uracil [9]
MR002522 5'-DFUR 5-fluorouracil Hydrolysis - Hydrolysis Capecitabine [10], [11]
MR010337 5'-DFUR 5-FU Unclear - Unclear Galocitabine [12]
⏷ Show the Full List of MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR006754 5-FU FdUMP Unclear Fluorouracilo [5]
MR006748 5-FU FUrd Unclear Fluorouracilo [5]
MR001055 5-fluorouracil 5,6-Dihydro-5-fluorouracil Reduction - Reduction Floxuridine [3], [4]
MR006734 5-FU FdUMP Unclear Flucytosine [5]
MR006728 5-FU FUrd Unclear Flucytosine [5]
MR005278 Fluorouracil 5-fluorouridine-triphosphate Conjugation - Phosphorylation Tegafur-uracil [9]
MR005273 Fluorouracil 5-FUH2 Oxidation - Dehydrogenation Tegafur-uracil [9]
MR002524 5-fluorouracil FUH2 Reduction - Reduction Capecitabine [11]
⏷ Show the Full List of MR
References
1 Phase I clinical trial of 5-fluoro-pyrimidinone (5FP), an oral prodrug of 5-fluorouracil (5FU)
2 Hplc-nmr identification of the human urinary metabolites of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analogue active against human immunodeficiency virus (HIV)
3 Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008 Sep-Oct;5(5):717-27.
4 The achievement of mass balance by simultaneous quantification of floxuridine prodrug, floxuridine, 5-fluorouracil, 5-dihydrouracil, -fluoro--ureidopropionate, -fluoro--alanine using LC-MS J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Apr 15;879(13-14):915-20. doi: 10.1016/j.jchromb.2011.02.045.
5 Study of the metabolism of flucytosine in Aspergillus species by 19F nuclear magnetic resonance spectroscopy
6 Phase I assessment of the pharmacokinetics, metabolism, and safety of emitefur in patients with refractory solid tumors
7 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
8 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
9 DrugBank(Pharmacology-Metabolism):Tegafur-uracil
10 EUCRISA? (crisaborole) ointment, 2%, for topical use
11 A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma
12 Measurement of ascorbic acid in human aqueous humour and plasma and bovine aqueous humour by high-performance liquid chromatography with electrochemical detection

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.